Login to Your Account

Transgene finds promise in NSCLC immunotherapy data

By Mari Serebrov
Washington Editor

Friday, January 10, 2014
Transgene SA was riding high Thursday after releasing top-line preliminary data from a Phase IIb/III study of TG4010, an immunotherapy being developed for non-small-cell lung cancer (NSCLC).

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription